Literature DB >> 33750592

National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.

Morgane Donadel1, Maria Susana Panero2, Lynnette Ametewee3, Abigail M Shefer2.   

Abstract

BACKGROUND: Competing priorities make using a transparent and evidence-based approach important when deciding to recommend new vaccines. We conducted a literature review to document the processes and frameworks for national decision-making on new vaccine introductions and explored which key features have evolved since 2010.
METHODS: We searched literature published on policymaking related to vaccine introduction from March 2010 to August 2020 in six databases. We screened articles for eligibility with the following exclusion criteria: non-human or hypothetical vaccines, the sole focus on economic evaluation or decision to adopt rather than policy decision-making. We employed nine broad categories of criteria from the 2012 review for categorization and abstracted data on the country, income level, vaccine, and other relevant criteria.
RESULTS: Of the 3808 unique references screened, 116 met eligibility criteria and were classified as: a) framework of vaccine adoption decision-making (27), b) studies that analyse empirical data on or examples of vaccine adoption decision-making (45), c) theoretical and empirical articles that provide insights into the vaccine policymaking process (44 + 17 already included in the previous categories). Commonly reported criteria for decision-making were the burden of disease; vaccine efficacy/effectiveness, safety; impact on health and non-health outcomes; economic evaluation and cost-effectiveness of alternative interventions. Programmatic and acceptability aspects were not as often considered. Most (50; 82%) of the 61 articles describing the process of vaccine introduction policymaking highlighted the role of country, regional, or global evidence-informed recommendations and a robust national governance as enabling factors for vaccine adoption.
CONCLUSIONS: The literature on vaccine adoption decision-making has expanded since 2010. We found that policymakers and expert advisory committee members (e.g., National Immunization Technical Advisory Group [NITAG]) increasingly value the interventions based on economic evaluations. The results of this review could guide discussions on evidence-informed immunization decision-making among country, sub-regional, and regional stakeholders. Published by Elsevier Ltd.

Entities:  

Keywords:  Evidence-based decision-making; Health system strengthening; Immunization programs; Infectious diseases; Systematic review; Vaccine policy

Year:  2021        PMID: 33750592     DOI: 10.1016/j.vaccine.2021.02.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.

Authors:  Jessica Price; Jessica Mooney; Carolyn Bain; John Tanko Bawa; Nikki Gurley; Amresh Kumar; Guwani Liyanage; Rouden Esau Mkisi; Chris Odero; Karim Seck; Evan Simpson; William P Hausdorff
Journal:  Vaccine       Date:  2021-12-02       Impact factor: 3.641

Review 2.  Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines.

Authors:  William P Hausdorff; Jessica Price; Frédéric Debellut; Jessica Mooney; Andrew A Torkelson; Khatuna Giorgadze; Clint Pecenka
Journal:  Vaccines (Basel)       Date:  2022-01-20

3.  Health actor approaches to financing universal coverage strategies for pneumococcal and rotavirus immunisation programmes in low-income and middle-income countries: a scoping review protocol.

Authors:  Shaza Fadel; Paula Braitstein; Oluwasegun Jko Ogundele; Erica Di Ruggiero
Journal:  BMJ Open       Date:  2021-12-14       Impact factor: 2.692

4.  Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.

Authors:  Jessica Mooney; Jessica Price; Carolyn Bain; John Tanko Bawa; Nikki Gurley; Amresh Kumar; Guwani Liyanage; Rouden Esau Mkisi; Chris Odero; Karim Seck; Evan Simpson; William P Hausdorff
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.